OmniAb, Inc. (OABI) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech industries. The company utilizes a proprietary platform called "Biological Intelligence" to create optimized antibody candidates. As of the reporting date, the company had 107 active partners and 409 active programs, including 27 antibodies in clinical development and 3 approved products.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $14.4 million | $4.2 million |
| Net Loss | $(7.7) million | $(18.2) million |
| Net Loss Per Share (Basic/Diluted) | $(0.06) | $(0.17) |
| Cash, Cash Equivalents & Short-Term Investments | $49.1 million | $34.0 million (approx.) |
| Operating Cash Flow | $(4.9) million | $(15.9) million |
| Research & Development Expenses | $9.6 million | $12.6 million |
| General & Administrative Expenses | $6.6 million | $7.9 million |
Note: The company reported no debt obligations in the form of long-term borrowings. Total liabilities were $31.0 million, primarily consisting of operating lease liabilities and deferred revenue.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by 247% to $14.4 million, driven primarily by a $10.0 million increase in license and milestone revenue.
- Improved Profitability: Net loss narrowed significantly by 58% to $7.7 million, aided by reduced operating expenses and higher revenue.
- Expense Reduction: R&D expenses decreased by 24% and G&A expenses by 16%, largely due to lower personnel costs and reduced share-based compensation.
- Intangible Asset Impairment: Amortization of intangibles increased by 87% to $6.0 million. This included a $2.9 million impairment charge related to the discontinuation of legacy small molecule ion channel programs.
- Cash Flow Improvement: Net cash used in operating activities improved by $11.0 million compared to the prior year.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash and short-term investments ($49.1 million) are sufficient to fund operations for at least the next 12 months.
- Capital Resources: The company completed a $30.0 million private placement (PIPE) in August 2025. An "At-The-Market" (ATM) facility with $88.3 million remaining capacity is available, though no shares were sold in Q1 2026.
- Warrants: Outstanding warrants (Public, Private, Forward Purchase, and Backstop) have an exercise price of $11.50. As of the report date, these are "out of the money" and not expected to be exercised in the near term.
- Risks: The company remains dependent on partners for the development and commercialization of its antibody candidates. Revenue timing is uncertain and heavily influenced by partner milestones and regulatory approvals. The company continues to incur losses as it invests in R&D.
Investor Verification Checklist
- Milestone Sustainability: Verify the source and sustainability of the $10.0 million milestone revenue spike to assess future revenue predictability.
- Impairment Details: Review the specific impact of the $2.9 million impairment on future R&D strategy and the discontinuation of ion channel programs.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the $49.1 million liquidity position to confirm the 12-month runway assertion.
- Partner Pipeline: Track the progression of the 27 clinical programs and 3 approved products, as these are the primary drivers for future royalty revenue.
- Share-Based Compensation: Note the reduction in share-based compensation expense and its impact on future non-cash charges and dilution.